Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

771.95INR
17 Jul 2019
Change (% chg)

Rs-7.60 (-0.97%)
Prev Close
Rs779.55
Open
Rs779.95
Day's High
Rs782.65
Day's Low
Rs768.00
Volume
783,581
Avg. Vol
1,888,574
52-wk High
Rs986.10
52-wk Low
Rs697.20

Latest Key Developments (Source: Significant Developments)

Lupin Gets Tentative U.S. FDA Approval For Mirabegron Er Tablets
Thursday, 27 Jun 2019 

June 27 (Reuters) - Lupin Ltd ::SAYS RECEIVES TENTATIVE U.S. FDA APPROVAL FOR MIRABEGRON ER TABLETS.DRUG INDICATED FOR TREATMENT OF OVERACTIVE BLADDER (GAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY.  Full Article

Lupin Says Japan PMDA Completes Inspection Of Mandideep Facility With No Critical, Major Observations
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Lupin Ltd ::JAPAN'S PMDA COMPLETES INSPECTION OF LUPIN'S MANDIDEEP FACILITY (UNIT-2).PMDA INSPECTION CLOSED WITH NO CRITICAL OR MAJOR OBSERVATIONS.INSPECTION WAS CONDUCTED BETWEEN MAY 14, 2019 AND MAY 17, 2019.  Full Article

Lupin Launches Budesonide Inhalation Suspension
Wednesday, 22 May 2019 

May 22 (Reuters) - Lupin Ltd ::SAYS LUPIN LAUNCHES BUDESONIDE INHALATION SUSPENSION.LUPIN LTD - DRUG INDICATED FOR THE MAINTENANCE TREATMENT OF ASTHMA AND AS PROPHYLACTIC THERAPY IN CHILDREN FROM 12 MONTHS TO 8 YEARS OF AGE.  Full Article

Lupin Says Hasn't Been Served Yet,Only Got Complaint In Lawsuit Against Pharma Cos In U.S.
Wednesday, 15 May 2019 

May 15 (Reuters) - Lupin Ltd ::SAYS HASN'T BEEN SERVED YET; HAS ONLY RECEIVED COMPLAINT IN LAWSUIT AGAINST PHARMA COS IN U.S..SAYS CONFIDENT OF DOUBLE DIGIT GROWTH IN INDIAN MARKET IN FY20.  Full Article

India's Lupin Posts March-Qtr Profit
Wednesday, 15 May 2019 

May 15 (Reuters) - Lupin Ltd ::MARCH QUARTER CONSOL NET PROFIT 2.90 BILLION RUPEES VERSUS LOSS OF 7.84 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL PROFIT WAS 4.18 BILLION RUPEES.MARCH QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 44.06 BILLION RUPEES VERSUS 40.34 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 5 RUPEES PER SHARE.  Full Article

India's Lupin Gets EIR For Pharmacovigilance Inspection From U.S. FDA
Tuesday, 14 May 2019 

May 14 (Reuters) - Lupin Ltd ::GETS EIR FOR PHARMACOVIGILANCE INSPECTION FROM U.S. FDA.INSPECTION WAS CONDUCTED AT CO'S GLOBAL PHARMACOVIGILANCE GROUP DSRM.INSPECTION CLOSED WITH FOUR OBSERVATIONS.  Full Article

Lupin Launches Clobazam Tablets
Friday, 10 May 2019 

May 10 (Reuters) - Lupin Ltd ::LUPIN LAUNCHES CLOBAZAM TABLETS.  Full Article

Lupin In Alliance With Natco Pharma Gets FDA Approval For Bosentan Tablets
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Lupin Ltd ::LUPIN IN ALLIANCE WITH NATCO RECEIVES FDA APPROVAL FOR BOSENTAN TABLETS.  Full Article

India's Lupin Gets FDA Approval For Testosterone Gel
Thursday, 11 Apr 2019 

April 11 (Reuters) - Lupin Ltd ::GETS FDA APPROVAL FOR TESTOSTERONE GEL.  Full Article

Lupin Launches Fluocinonide Ointment USP 0.05 Pct
Thursday, 28 Mar 2019 

March 28 (Reuters) - Lupin Ltd ::LUPIN LAUNCHES FLUOCINONIDE OINTMENT USP 0.05%.  Full Article

BUZZ-Lupin falls after U.S. FDA classification of Goa plant, potential approval curbs

** Indian drugmaker Lupin Ltd's shares fall as much as 5.7% to 720 rupees - lowest since March 28